-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on HeartSciences, Raises Price Target to $9.2

Benzinga·12/22/2025 10:38:45
语音播报
Ascendiant Capital analyst Lucas Ward maintains HeartSciences (NASDAQ:HSCS) with a Buy and raises the price target from $9 to $9.2.